FDA Lifts Clinical Hold on Vion's Phase III Trial of Leukemia Drug
Posted on: Wednesday, 9 January 2008, 12:01 CST
Vion Pharmaceuticals has reported that the FDA has lifted the clinical hold on the Phase III trial of its lead anti-cancer agent, Cloretazine, in combination with cytarabine in relapsed acute myelogenous leukemia.
While this trial remains blinded overall, a portion of data on 210 patients was unblinded for review at interim analysis. The company's medical consultants and external independent reviewers performed a comprehensive safety analysis of Vion Study CLI-037. This analysis concluded that the combined myelosuppressive effects of Cloretazine (VNP40101M) and cytarabine given at the dose and schedule at which they were combined in the trial, in conjunction with the poor hematologic reserve of patients with relapsed acute myelogenous leukemia (AML), were major factors in the difference in mortality seen between the two arms of the study.
There was an increase in the response rate observed on the Cloretazine (VNP40101M) and cytarabine arm of the trial relative to the cytarabine and placebo arm, despite the difference in deaths between the two arms. An agreement has been reached with the FDA on modifications to Vion Study CLI-037. The revised study includes a lower dose of Cloretazine (VNP40101M) in the experimental arm of the trial and prophylactic therapy with antibiotics, antifungals and growth factors for all patients. In order to maintain the special protocol assessment (SPA) with the FDA for this trial, the next step is to submit an SPA to the FDA with these modifications before recommencing the trial.
Frank Giles, lead investigator on the Cloretazine clinical program, said: "Modifications to this Phase III trial in patients with relapsed AML will allow us to examine a combination schedule that should maintain the activity observed in the initial portion of the study with an acceptable marrow toxicity profile."
Source: Datamonitor
Related Articles
- Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients With Relapsing Multiple Sclerosis
- Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
- Study Shows That High-Dose, High-Frequency Interferon Produces No Additional Benefit on Efficacy Compared to AVONEX(R) (Interferon Beta-1a) in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
- Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
- BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
- Data From Phase I Clinical Trial of QUADRAMET(R) in Patients With Relapsed Multiple Myeloma Presented at the 11th Congress of the European Hematology Association
- Cytogen Announces Positive Interim Findings From a Phase I Clinical Trial of QUADRAMET(R) Combination Study in Patients With Relapsed Multiple Myeloma
- Phase II Study Demonstrates That ONTAK(R) Benefits Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma
- Phase II Data Show Combination Biological Therapy With Galiximab and RITUXAN is Well-Tolerated and May Extend Event-Free Survival in Patients With Relapsed or Refractory, Follicular Lymphoma
 |
 |
User Comments (0)
RSS Feeds